Alpha 2.0
Login Register
» Authors » H Scher

H Scher

Explore the profile of H Scher including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 76
Citations 843
Followers 0
Related Specialties
Oncology
Psychiatry
Urology
Top 10 Co-Authors
J J Furedy
A Yagoda
H Herr
D Bajorin
G Bosl
C Sternberg
C Cordon-Cardo
R J Heslegrave
C N Sternberg
V Reuter
Published In
J Clin Oncol
Psychophysiology
Cancer Res
Arch Sex Behav
Prostate Cancer Prostatic Dis
Affiliations
Soon will be listed here.
Recent Articles
1.
The role of silica nanoparticles on long-term room-temperature stabilization of water-in-oil emulsions containing microalgae
Fernandez L, Scher H, VanderGheynst J
Lett Appl Microbiol . 2015 Sep; 61(6):568-72. PMID: 26388196
Unlabelled: Prior research has demonstrated that microalgae can be stored for extended periods of time at room temperature in water-in-oil (W/O) emulsions stabilized by surface modified silica nanoparticles. However, little...
2.
An analysis of the association between prostate cancer risk loci, PSA levels, disease aggressiveness and disease-specific mortality
Sullivan J, Kopp R, Stratton K, Manschreck C, Corines M, Rau-Murthy R, et al.
Br J Cancer . 2015 Jun; 113(1):166-72. PMID: 26068399
Background: Genome-wide association studies have identified multiple single-nucleotide polymorphsims (SNPs) associated with prostate cancer (PCa). Although these SNPs have been clearly associated with disease risk, their relationship with clinical outcomes...
3.
Reproducibility and clinical correlations of post-treatment changes on CT of prostate cancer bone metastases treated with chemotherapy
Gourtsoyianni S, Hwang S, Panicek D, Zheng J, Moskowitz C, Scher H, et al.
Br J Radiol . 2012 Aug; 85(1017):1243-9. PMID: 22919006
Objectives: The objective of this study was to determine whether, in patients with prostate cancer (PCa) bone metastases receiving chemotherapy, early post-treatment changes on CT are reproducible and associated with...
4.
Expression and sequence analysis of the SDI1/WAF1/CIP1/p21 tumor suppressor gene in prostate cancer cell lines
Papandreou C, Bogenrieder T, Scher H, Albino A, Nanus D
Int J Oncol . 2011 May; 8(6):1237-41. PMID: 21544489
The SDI1/WAF1/CIP1 gene encodes a M(r) 21,000 protein (p21) that can arrest cell growth by associating with and inhibiting cyclin-dependent kinase complexes necessary for cells to exit G(1). It is...
5.
An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib
Stubblefield M, Slovin S, MacGregor-Cortelli B, Muzzy J, Scher H, Wright J, et al.
Clin Oncol (R Coll Radiol) . 2006 Jul; 18(5):410-8. PMID: 16817333
Aims: Bortezomib (Velcade), a novel proteasome inhibitor, has shown promise in the treatment of malignancies, including multiple myeloma and non-Hodgkin's lymphoma. Several studies have identified neuropathy as a potentially dose-limiting...
6.
A Coordinate System for Lesion Mapping and Distribution in Progressive Prostate Cancer Using Positron Emission Tomography (PET)
Srivastava N, Erdi Y, Divgi C, Scher H, Larson S
Clin Positron Imaging . 2003 Oct; 2(6):348. PMID: 14516645
No abstract available.
7.
Editorial
Kirby R, Brawer M, Scher H
Prostate Cancer Prostatic Dis . 2002 Dec; 2(5/6):218. PMID: 12497165
No abstract available.
8.
Editorial
Kirby R, Scher H, Brawer M
Prostate Cancer Prostatic Dis . 2002 Dec; 1(2):47. PMID: 12496914
No abstract available.
9.
Editorial
Kirby R, Scher H, Brawer M
Prostate Cancer Prostatic Dis . 2002 Dec; 2(2):58. PMID: 12496836
No abstract available.
10.
Local detection of prostate cancer by positron emission tomography with 2-fluorodeoxyglucose: comparison of filtered back projection and iterative reconstruction with segmented attenuation correction
Turlakow A, Larson S, Coakley F, Akhurst T, Gonen M, Macapinlac H, et al.
Q J Nucl Med . 2002 Jan; 45(3):235-44. PMID: 11788816
Background: To compare filtered back projection (FBP) and iterative reconstruction with segmented attenuation correction (IRSAC) in the local imaging of prostate cancer by positron emission tomography with 2-fluorodeoxyglucose (FDG-PET). Methods:...